Lanreotide Completed Phase 4 Trials for Acromegaly Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00701363Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00627796Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00216398Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00149188Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00145405Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction